CST1, DCC1, IFITM1 or MELK as markers for diagnosing stomach cancer
US9075066B2 · kind B2 · utility
0Cited by
2References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 21, 2009 |
| Grant date | Jul 7, 2015 |
| Priority date | — |
| Expiry date | Aug 13, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/04
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to a biomarker for gastric cancer, CST1 (cysteine proteinase inhibitor, type 2 family), DCC1 (Defective in sister chromatid cohesion homolog 1), IFITM1 (interferon induced transmembrane protein 1) or MELK (maternal embryonic leucine zipper kinase). More particularly, the present invention relates to a diagnostic composition for gastric cancer comprising an agent measuring the expression level of CST1, DCC1, IFITM1 or MELK, a kit comprising the composition, a method for detecting the marker, and a method for screening a therapeutic agent for gastric cancer using the marker.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.